Results 11 to 20 of about 1,890 (188)

Does CytoSorb Interfere With Immunosuppression? A Pharmacokinetic and Functional Evaluation [PDF]

Pharmaceutics
Background/Objectives: Cytokine release during organ transplantation contributes to primary graft dysfunction and requires careful immunomodulation. CytoSorb, a hemoadsorption device developed to reduce circulating cytokine levels, is increasingly used ...
Viktoria Weber, Claudia Schildböck, Jens Hartmann   +2 more
exaly   +7 more sources

The use of CytoSorb hemoadsorption in critically ill patients: a narrative review [PDF]

Frontiers in Medicine
Inflammation, a complex biological response against injury or infection, is an important pathological basis for various critical diseases. A “normal” immune response exemplifies a balanced dialogue between immunological cells and a medley of pro- and ...
Kaixin Lei, Ao Chen, Xinqi An, Jun Guo, Baihai Su, Baihai Su, Baihai Su, Yupei Li   +7 more
doaj   +6 more sources

Impact of CytoSorb® on Interleukin-6 in Cardiac Surgery

Frontiers in Cardiovascular Medicine, 2023
ObjectiveCardiac surgery is known to activate a cascade of inflammatory mediators leading to a systemic inflammatory response. Hemadsorption (HA) devices such as CytoSorb® have been postulated to mitigate an overshooting immune response, which is ...
Daniela Geisler, Markus Mach
exaly   +5 more sources

Hematological parameter dynamics in critically ill patients treated with oXiris®-based CRRT and CytoSorb® hemoadsorption: a prospective single-center study [PDF]

BMC Nephrology
Background Hemoadsorption is increasingly used as adjunctive extracorporeal support in sepsis and septic shock. Comparative data on device-specific hematologic effects remain limited. CytoSorb® and oXiris® are among the most widely applied hemoadsorption
Nikolina Špirić, Katarina Vučićević, Jesús Villar, Tijana Kovačević, Saša Dragić, Biljana Zlojuto, Danica Momčičević, Milka Jandrić, Grozdana Klječanin, Pedja Kovačević   +9 more
doaj   +3 more sources

CytoSorb^® Hemadsorption During Microaxial Flow Pump (mAFP) Support in Cardiogenic Shock: A Propensity Score-Matched Cohort Study [PDF]

Biomedicines
Background: Despite advances in temporary mechanical circulatory support (tMCS), patients with cardiogenic shock (CS) who are treated with a microaxial flow pump (mAFP; Impella®, Abiomed) still have a high mortality rate.
Julian Kreutz, Klevis Mihali, Lukas Harbaum, Georgios Chatzis, Nikolaos Patsalis, Styliani Syntila, Bernhard Schieffer, Birgit Markus   +7 more
doaj   +3 more sources

Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure

Scientific Reports
CytoSorb is a hemoadsorptive column used to remove high concentrations of proinflammatory cytokines in septic shock. Data on CytoSorb application in acute-on-chronic liver failure (ACLF) is lacking. This retrospective observational study analyzed 21 ACLF
Patrick Haselwanter, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Marlene Riedl-Wewalka, Monika Schmid, Thomas Reiberger, Christian Zauner, Mathias Schneeweiss-Gleixner   +8 more
doaj   +4 more sources

Applications of Cytosorb in clinical practice [PDF]

Journal of Pre-Clinical and Clinical Research, 2019
Introduction and objective. Cytososorb is haemadsorption device approved in the European Union in 2011 for cytokine adsorption. Recently, in 2018, new indications for the device use have been added, including bilirubin and myoglobin removal.
Paweł Kutnik, Michał Borys
openaire   +3 more sources

Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study [PDF]

Annals of Intensive Care, 2022
Background Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb® unintentionally adsorbs vancomycin.
Christina Scharf, Ferdinand Weinelt, Ines Schroeder, Michael Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Charlotte Kloft, Josef Briegel, Uwe Liebchen   +9 more
doaj   +2 more sources

Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial [PDF]

BMJ Open, 2022
Introduction Vasoplegia is a common complication after cardiac surgery and is associated with poor prognosis. It is characterised by refractory hypotension despite normal or even increased cardiac output. The pathophysiology is complex and includes the systemic inflammatory response caused by cardiopulmonary ...
Papazisi, O., Bruggemans, E.F., Berendsen, R.R., Hugo, J.D.V., Lindeman, J.H.N., Beeres, S.L.M.A., Arbous, M.S., Hout, W.B. van den, Mertens, B.J.A., Ince, C., Klautz, R.J.M., Palmen, M.   +11 more
core   +9 more sources

To Hemoadsorb or Not to Hemoadsorb—Do We Have the Answer Yet? An Updated Meta-Analysis on the Use of CytoSorb in Sepsis and Septic Shock

Biomedicines
Severe inflammation leading to organ dysfunction is the cornerstone of the pathophysiology of sepsis. Thus, from a theoretical point of view, rebalancing inflammation has the potential to improve patient outcomes.
Mihai Popescu, Romina-Marina Sima, Tudor Borjog   +2 more
exaly   +4 more sources